Cancer Clinical Trials
Find a clinical trial, talk with your doctor to learn if you are eligible.
Updated June 2022
| Cancer Type | Trial Name | Site |
|---|---|---|
| Breast |
NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer. | Norwalk/Danbury |
| OTS1070103: A Phase I Study of OTS167PO,a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast cancer | Norwalk | |
| SGNLVA-001: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer | Norwalk | |
| SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer | Norwalk | |
| A011202: A Randomized, Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy |
Norwalk/VBMC | |
| ARV-471-mBC-101: A Phase 1/2, open label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting | Norwalk | |
| 18-002: A Phase I Study of Rucaparib Administered Concurrently with Postoperative Radiotherapy in Patients with Triple Negative Breast Cancer with an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy | Norwalk | |
| 18-109: A Feasibility Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromotase Inhibitors | Norwalk | |
| 19-401: Triple Negative Breast Cancer Clinic Program at Norwalk Hospital | Norwalk | |
| A011801: The COMPASSHER2 Trials ( COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatnib. |
Norwalk/Danbury |
|
| A191901:Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions |
Norwalk/Danbury |
|
| Breast & Lung | 18-486 PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic Breast or Lung Cancer | Norwalk |
| Lung | A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial |
Danbury/VBMC |
| E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
Danbury/VBMC | |
| Thoracic Surgery | IELCART: Initiative for Early Lung Cancer Research on Treatment |
VBMC |
| PLOTS: Intraoperative, Percutaneous Localization of Peripheral Pulmonary Nodules for Resection: A Prospective, Open-Label, Multi-Center Registry Study of Thoracic Surgery Outcomes |
VBMC | |
| GYN |
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer |
Danbury/Norwalk |
| NRG-GY020: “Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer. |
Danbury/Norwalk | |
| NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] | Danbury/Norwalk | |
| NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab | Danbury/Norwalk | |
| Pancreas | 15-10: The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer |
Norwalk/Danbury/New Milford |
| 16-15: Pre- and Post-Surgical Molecular Testing in Individuals with Operable Pancreatic Cancer |
Norwalk/Danbury/New Milford |
|
| 16-17: A Pancreatic Cancer Screening Study in High Risk Individuals |
Norwalk/Danbury/New Milford |
|
| 18-01: A Pancreatic Cancer Screening Study in High Risk Individuals Including those with Recent-Onset Diabetes Mellitus |
Norwalk/Danbury/New Milford |
|
| A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer |
Norwalk/Danbury |
|
| TD2-PDAC-KETO-001: Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer |
Norwalk/Danbury |
|
| S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations | Norwalk/Danbury | |
| Translational |
15-35: Serum-based Signature of Activation of the PD-1/PD-L1 Pathway in Patients with Cancer. Serial serum samples from patients starting immune-based therapies that target the PD-1/PDL-1 pathway in cancer patients. |
Norwalk/Danbury/New Milford |
| BB001: The Western Connecticut Health Network (WCHN), Danbury and Norwalk Hospitals Biobank - A Collection of Biospecimens and Clinical Data to Facilitate Research (GYN Biobank) |
Norwalk/Danbury/New Milford | |
| S2013: “Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study” | Norwalk/Danbury |
|
| 2200003: A Prospective Study to Achieve Health Equity in Biomarker Analysis for Underrepresented Communities Receiving Cancer Treatment at Nuvance Health |
Norwalk/Danbury |
|
| Basket Trial |
C2321001: A Phase I dose escalation and expanded cohort study of PF-06821497 in the treatment of adult patients with Relapsed/refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and follicular lymphoma | Norwalk |
| AMG 510 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation |
Norwalk | |
| ONC-392-001: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. |
Norwalk/Danbury |
Related Articles
1 of